Evofem Biosciences Changes Principal Executive Offices
Ticker: EVFM · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1618835
Sentiment: neutral
Topics: administrative, office-move
TL;DR
Evofem moved offices to San Diego, CA effective 12/23/24.
AI Summary
On December 23, 2024, Evofem Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 7770 Regents Road, Suite 113-618, San Diego, California 92122. This move is effective as of December 23, 2024.
Why It Matters
A change in principal executive offices can signal operational shifts or cost-saving measures for the company.
Risk Assessment
Risk Level: low — This filing is a routine administrative update regarding office location and does not involve significant financial or operational changes.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- December 23, 2024 (date) — Effective date of office change
- 7770 Regents Road , Suite 113-618 San Diego , California 92122 (location) — New principal executive offices
FAQ
What is the new address for Evofem Biosciences' principal executive offices?
The new address is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
When did this change of address become effective?
The change of address became effective on December 23, 2024.
Is this a change in the company's legal domicile or state of incorporation?
No, the filing states the company is incorporated in Delaware and this is a change in principal executive offices.
What was the former address of Evofem Biosciences?
The filing does not explicitly state the former address, only that the principal executive offices have changed.
What is the primary business of Evofem Biosciences?
Evofem Biosciences is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 393 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-12-23 06:05:53
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-k.htm (8-K) — 32KB
- 0001493152-24-051174.txt ( ) — 201KB
- evfm-20241223.xsd (EX-101.SCH) — 3KB
- evfm-20241223_lab.xml (EX-101.LAB) — 33KB
- evfm-20241223_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: December 23, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer